Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (301-310 of 440) with videos related to

Pageof 44
Sort By:
Molecular Cell|October 7, 2019
γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2AXue Gao, Liang Zhao, Shuangping Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple MyelomaBenjamin G Barwick, Vikas A Gupta, Shannon M Matulis, et al.
Transfusion|June 10, 2010
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host diseaseMojtaba Akhtari, Cynthia R Giver, Zahir Ali, et al.
Clinical Advances in Hematology & Oncology : H&O|December 6, 2007
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedingsEdward A Stadtmauer, Sagar Lonial, David H Vesole, et al.
Ophthalmology and Therapy|September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
The Journal of Clinical Investigation|May 14, 2019
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balanceChaoyun Pan, Lingtao Jin, Xu Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed PhenotypeTaofeek K Owonikoko, Bhakti Dwivedi, Zhengjia Chen, et al.
Molecular Cell|March 17, 2018
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma CellsRuiting Lin, Siyuan Xia, Changliang Shan, et al.
Pageof 44

Showing results (301-310 of 440) with videos related to

Sort By:
Pageof 44
Molecular Cell|October 7, 2019
γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2AXue Gao, Liang Zhao, Shuangping Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple MyelomaBenjamin G Barwick, Vikas A Gupta, Shannon M Matulis, et al.
Transfusion|June 10, 2010
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host diseaseMojtaba Akhtari, Cynthia R Giver, Zahir Ali, et al.
Clinical Advances in Hematology & Oncology : H&O|December 6, 2007
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedingsEdward A Stadtmauer, Sagar Lonial, David H Vesole, et al.
Ophthalmology and Therapy|September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
The Journal of Clinical Investigation|May 14, 2019
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balanceChaoyun Pan, Lingtao Jin, Xu Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed PhenotypeTaofeek K Owonikoko, Bhakti Dwivedi, Zhengjia Chen, et al.
Molecular Cell|March 17, 2018
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma CellsRuiting Lin, Siyuan Xia, Changliang Shan, et al.
Pageof 44